PMID- 32831120
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Aug 24
TI  - Efficacy and safety of recombinant human endostatin combined with radiotherapy or 
      chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a 
      pooled analysis.
PG  - 205
LID - 10.1186/s13014-020-01646-9 [doi]
LID - 205
AB  - PURPOSE: To assess the efficacy and safety of recombinant human endostatin in 
      combination with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) in 
      patients with locally advanced non-small cell lung cancer (LA-NSCLC). METHODS: We 
      searched eligible literature in available databases using combinations of the 
      following search terms: lung cancer, endostatin or endostar, radiotherapy or 
      radiation therapy or chemoradiotherapy. The inclusion criteria were: prospective 
      or retrospective (including single-arm) studies that evaluated the efficacy and 
      safety of endostatin plus radiotherapy (ERT) or concurrent chemoradiotherapy 
      (ECRT) in patients with LA-NSCLC. Primary outcomes included the following: 
      objective response rate (ORR), local control rates (LCR), overall survival (OS), 
      progression-free survival (PFS), and adverse events (AEs). Tests of 
      heterogeneity, sensitivity, and publication bias were performed. RESULTS: A total 
      of 271 patients with LA-NSCLC from 7 studies were enrolled, including six 
      prospective trials and one retrospective study. The pooled median PFS was 
      11.3 months overall, 11.2 months in the ECRT group, and 11.8 months in the ERT 
      group. Pooled median OS and ORR were 18.9 months and 77.2% overall, 18.4 months 
      and 77.5% in the ECRT group, and 19.6 months and 76.1% in the ERT group, 
      respectively. The incidences of major grade >/= 3 AEs for all patients, subgroups 
      of ECRT and ERT were 10.9% vs 11.9% vs 9.4% for radiation pneumonitis, 11.6% vs 
      12.2% vs 9.4% for radiation esophagitis, 35.5% vs 43.4% vs 0 for leukopenia, 
      27.8% vs 40.7% vs 2.1% for neutropenia, and 10.5% vs 12.3% vs 2.1% for anemia. 
      CONCLUSIONS: Combined endostatin with RT or CCRT is effective and well tolerated 
      in treating LA-NSCLC, and less toxicities occur. Further validation through 
      prospective randomized control trials is required.
FAU - Zhang, Shu-Ling
AU  - Zhang SL
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      110004, China.
FAU - Han, Cheng-Bo
AU  - Han CB
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      110004, China.
FAU - Sun, Li
AU  - Sun L
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      110004, China.
FAU - Huang, Le-Tian
AU  - Huang LT
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      110004, China.
FAU - Ma, Jie-Tao
AU  - Ma JT
AD  - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 
      110004, China. ma_jt@126.com.
LA  - eng
GR  - 81501990/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200824
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
RN  - 0 (Endostatins)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/pathology/*therapy
MH  - Chemoradiotherapy/*methods
MH  - Combined Modality Therapy
MH  - Endostatins/*administration & dosage
MH  - Humans
MH  - Lung Neoplasms/pathology/*therapy
MH  - Prognosis
MH  - Recombinant Proteins/*administration & dosage
PMC - PMC7446219
OTO - NOTNLM
OT  - Chemoradiotherapy
OT  - Endostatin
OT  - Non-small cell lung cancer
OT  - Radiotherapy
COIS- The authors declare that they have no competing interests.
EDAT- 2020/08/25 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/08/24
CRDT- 2020/08/25 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/08/24 00:00 [pmc-release]
AID - 10.1186/s13014-020-01646-9 [pii]
AID - 1646 [pii]
AID - 10.1186/s13014-020-01646-9 [doi]
PST - epublish
SO  - Radiat Oncol. 2020 Aug 24;15(1):205. doi: 10.1186/s13014-020-01646-9.